AR029308A1 - Compuestos de sulfonamidas, composiciones farmaceuticas formuladas con dichos compuestos y uso de los compuestos mencionados para la preparacion de dichas composiciones para potenciar la funcion glutamato receptora - Google Patents

Compuestos de sulfonamidas, composiciones farmaceuticas formuladas con dichos compuestos y uso de los compuestos mencionados para la preparacion de dichas composiciones para potenciar la funcion glutamato receptora

Info

Publication number
AR029308A1
AR029308A1 ARP990103725A ARP990103725A AR029308A1 AR 029308 A1 AR029308 A1 AR 029308A1 AR P990103725 A ARP990103725 A AR P990103725A AR P990103725 A ARP990103725 A AR P990103725A AR 029308 A1 AR029308 A1 AR 029308A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
compounds
hydrogen
conh
Prior art date
Application number
ARP990103725A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR029308A1 publication Critical patent/AR029308A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se trata de compuestos de sulfonamidas de formula (1) en donde La representa alquileno (C1-4); Lb representa alquilen (C1-4); Lc representa alquilen (C1-4); r es cero o 1; m es cero o 1; n es cero o 1, q es 1 o 2; X1 representa O, S, NR9, C (=O), OCO, COO, NHCO2, O2CNH, CONH, NHCO, SO o SO2; X2 representa O, S, NR10, C(=O), OCO, COO, NHCO2, O2CNH, CONH, NHCO, SO o SO2, X3 representa O, S, NR11, C (=O), NHCO2, O2CNH, CONH, NHCO, SO, SO2; R1 representa un átomo de hidrogeno, un grupo alquilo (C1-4), un grupo cicloalquilo (C3-8), un grupo aromático opcionalmente sustituido, un grupo heteroaromático opcionalmente sustituido, o un anillo heterocíclico de 4 a 7 miembros saturados, que contiene al grupo NR10 o un grupo X como los unicos miembros de hetero anillo, en donde X representa -CH2-, CO, O, S, o NR12 y R12 representa hidrogeno o (C1-4); R9 es hidrogeno o alquilo (C1-4); R10 es hidrogeno o alquilo (C1-4), o R1 y R10 juntamente con el átomo de nitrogeno al cual se encuentran unidos forman un grupo azetidinilo, pirrolidinilo, piperidinilo, di (C1-4) alquilaminopiperidinilo, morfolino, piperazinilo o N-(C1-4) alquilpiperazinilo; R11 es hidrogeno o alquilo (C1-4); R2 representa alquilo (C1-6), cicloalquilo (C3-6), fluoralquilo (C1-6), cloroalquilo (C1-6), alquenilo (C2-6), alcoxi (C1-4), alquilo (C1-4), fenilo que es no sustituido o sustituido por halogeno, alquilo (C1-4) o alcoxi (C1-4) o un grupo de la formula: R3R4N, en donde R3 y R4 cada uno independientemente representa alquilo (C1-4) o, juntamente con el átomo de nitrogeno al cual se encuentran unidos forman un grupo azetinidino, pirrolidinilo, piperidinilo, morfolino, piperazinilo, hexahidroazepinilo o octahidroazocinilo; y Cualquiera entre R5, R6, R7 y R8 representan hidrogeno, alquilo (C1-6); (C1-6) arilo; alquenilo (C2-6), arilo (C2-6) alquenilo o arilo, o dos entre R5, R6, R7, y R8 juntamente con el átomo de carbono o átomos de carbono a los cuales se encuentran unidos forman un anillo carbocíclico (C3-8); y el resto de R5, R6, R7 y R8 representan hidrogeno; o una sal farmacéuticamente aceptable de los mismos. Siempre que (1) si m representa cero, entonces X1 representa (C =O) CONH, o CONH, o SO2, X2 representa NR10 y R1 y R10 juntamente con el átomo de nitrogeno al cual se encuentra unidos forman un grupo azetidinilo, piperidinilo, 4-di(C1-4) alquilaminopiperidinilo, piperazinilo o N-(C1-4)alquilpiperazinilo, y (2) si el grupo -X2-(La)m-(X3Lc)r-X1-(Lb)N- representa -OCH2CONH-, entonces R1 no representa un grupo aromático opcionalmente sustituido o un grupo heteroaromático opcionalmente sustituido. Dichos compuestos son utiles para preparar composiciones farmacéuticas para potenciar la funcion de los glutamatos receptores. También se proponen los objetos presentados en el título de esta solicitud.
ARP990103725A 1998-07-31 1999-07-28 Compuestos de sulfonamidas, composiciones farmaceuticas formuladas con dichos compuestos y uso de los compuestos mencionados para la preparacion de dichas composiciones para potenciar la funcion glutamato receptora AR029308A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9497398P 1998-07-31 1998-07-31

Publications (1)

Publication Number Publication Date
AR029308A1 true AR029308A1 (es) 2003-06-25

Family

ID=22248268

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103725A AR029308A1 (es) 1998-07-31 1999-07-28 Compuestos de sulfonamidas, composiciones farmaceuticas formuladas con dichos compuestos y uso de los compuestos mencionados para la preparacion de dichas composiciones para potenciar la funcion glutamato receptora

Country Status (12)

Country Link
EP (1) EP0994110B1 (es)
JP (1) JP2002521438A (es)
AR (1) AR029308A1 (es)
AT (1) ATE240308T1 (es)
AU (1) AU5233499A (es)
CA (1) CA2339091A1 (es)
CO (1) CO5080793A1 (es)
DE (1) DE69907845T2 (es)
ES (1) ES2199525T3 (es)
PE (1) PE20000943A1 (es)
SV (1) SV1999000117A (es)
WO (1) WO2000006148A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
AU5235599A (en) 1998-07-31 2000-02-21 Eli Lilly And Company N-substituted sulfonamide derivatives
US6358981B1 (en) 1998-07-31 2002-03-19 Eli Lilly And Company Sulphonamide derivatives
BR0010183A (pt) 1999-04-30 2002-01-08 Lilly Co Eli Derivados de monofluoroalquila
US6639107B1 (en) 1999-12-08 2003-10-28 Eli Lilly And Company Cyclopentyl sulfonamide derivatives
MXPA02010021A (es) 2000-05-19 2003-02-12 Lilly Co Eli Derivados de sulfonamida.
JP2004530680A (ja) * 2001-05-04 2004-10-07 イーライ・リリー・アンド・カンパニー ２型糖尿病治療薬製造のためのａｍｐａ受容体増強物質の使用
WO2002098846A1 (en) * 2001-06-05 2002-12-12 Eli Lilly And Company Sulfonamide derivatives
AU2014277952A1 (en) 2013-06-13 2016-01-28 Veroscience Llc Compositions and methods for treating metabolic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5103054A (en) * 1990-05-03 1992-04-07 Ethyl Corporation Tertiary sulfonamides
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
CA2212829A1 (en) * 1995-02-21 1996-08-29 Jiro Takeo Glutamic acid receptor agonist
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives

Also Published As

Publication number Publication date
ATE240308T1 (de) 2003-05-15
JP2002521438A (ja) 2002-07-16
CA2339091A1 (en) 2000-02-10
EP0994110A1 (en) 2000-04-19
WO2000006148A1 (en) 2000-02-10
SV1999000117A (es) 2000-10-09
DE69907845T2 (de) 2004-05-06
CO5080793A1 (es) 2001-09-25
PE20000943A1 (es) 2000-09-28
EP0994110B1 (en) 2003-05-14
ES2199525T3 (es) 2004-02-16
DE69907845D1 (de) 2003-06-18
AU5233499A (en) 2000-02-21

Similar Documents

Publication Publication Date Title
AR011623A1 (es) Compuestos de sulfonamidas, procedimiento para prepararlos y composiciones farmaceuticas para potenciar las funciones de los glutamatoreceptores enmamiferos.
AU2001272476A1 (en) Piperidines for use as orexin receptor antagonists
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
SG147436A1 (en) Muscarinic acetylcholine receptor antagonists
AR016666A1 (es) Derivados de pirimidinona, un procedimiento para su preparacion y una composicion farmaceutica que los contiene
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
RS50904B (sr) Derivati tropana i njihova primena
DE69903976D1 (de) Heteroaryl-zyklische acetale
NO20022683D0 (no) Ureaforbindelser med muskarinisk reseptor-antagonistaktivitet
AR025386A1 (es) Moduladores de los receptores activados del proliferador de peroxisomas
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR035497A1 (es) Compuestos no-imidazol, composicion farmaceutica que los comprenden y el uso de los mismos para la preparacion de medicamentos
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
AR035068A1 (es) Compuestos de pirimidinona, composiciones farmaceuticas que los comprenden, uso de tales compuestos en la fabricacion de medicamentos y proceso para la preparacion de dichos compuestos
BR0309397A (pt) Derivados de n-[fenil(piperidin-2-il)metil]benzamida, sua preparação e sua aplicação em terapia
AR015528A1 (es) Compuestos heterociclicos como inhibidores de enzimas rotamasas, composiciones, su uso para la preparacion de medicinas, proceso para su preparacion ycompuestos intermediarios
AR029308A1 (es) Compuestos de sulfonamidas, composiciones farmaceuticas formuladas con dichos compuestos y uso de los compuestos mencionados para la preparacion de dichas composiciones para potenciar la funcion glutamato receptora
AR026351A1 (es) Derivados de pirrol como inhibidores de la fosfodiesterasa vii
DE3782687D1 (de) Aminoimidazochinolin-derivate.
AR054121A1 (es) Compuestos de fenilpiridilpiperazina, procedimiento de preparacion, composiciones farmaceuticas que los contienen, y usos farmacologicos como antagonistas de receptores histaminergicos h3
ES2058531T3 (es) Amidas de mercapto-fenilalcanoilaminoacidos, su preparacion y su uso como inhibidores de colagenasa.
CO5251384A1 (es) Derivados de piperazina sustituidos, su preparacion y su empleo como medicamentos
ATE82959T1 (de) N-(2-alkyl-3-mercapto-1,5-dioxoalkyl)glycinamid derivate und deren verwendung als kollagenaseinhibitoren.
KR950702978A (ko) 아미드 유도체(Amide derivatives)
CO5080761A1 (es) Inhibidores de lad fkbp na inhibidores de las fkbp